Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-371-500"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pl"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-371-500"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-372-0002
lpv:speaker	lp:Michał Tomasz Kamiński2
lpv:spokenAs	unknown; Polska Jest Najważniejsza (2011-02-21--2014-01-13)3,3 substitute; AFET (2012-01-19--2014-06-30)3,3 member; DEVE (2012-01-19--2014-06-30)3,3 member; Delegation for relations with the Mercosur countries (2009-09-16--2014-06-30)3,3 member; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3,3 member_of_the_bureau; PECH (2011-03-09--2014-02-03)3,3 substitute; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3,3 substitute; Delegation to the EU-Armenia, EU-Azerbaijan and EU-Georgia Parliamentary Cooperation Committees (2009-09-16--2014-06-30)3,3
lpv:translated text	"I endorsed the McAvan report because I think that the welfare of the EU’s patients is a priority. To protect our citizens, we should learn from our mistakes and change EU law so that we can react quickly to any kind of threat. As we all know, many criminal investigations are under way in France relating to the medicine Mediator. The amendments to current pharmacovigilance legislation proposed by the Commission in the wake of the Mediator case are a move in the right direction, but I agree with the statement that further changes are needed to close any potential loopholes. I support the Commission’s proposals, which improve pharmacovigilance at EU level."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph